- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01263145
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer
Studienübersicht
Status
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of the combination of MK-2206 and weekly paclitaxel. (Dose-escalation phase) II. To determine the safety and anti-tumor activity of the combination in metastatic breast cancer. (Expansion phase)
SECONDARY OBJECTIVES:
I. To determine the pharmacokinetics of MK-2206 and weekly paclitaxel used in combination.
II. To determine the safety of MK-2206 and weekly paclitaxel used in combination.
III. To evaluate the toxicities and tolerability of the combination. IV. To document anti-tumor activity. V. To determine baseline molecular markers that may predict clinical activity. VI. To determine pharmacodynamic markers in blood and tumor tissue that may predict an increase in apoptosis (by cleaved caspase 3) and clinical activity.
VII. To determine concordance of phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) and phosphatase and tensin homolog (PTEN) status between primary tumor and distant metastasis.
VIII. To determine concordance of PIK3CA status of circulating tumor cells and distant metastasis.
OUTLINE: This is a dose-escalation study of Akt inhibitor MK2206.
Patients receive paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15 and Akt inhibitor MK2206 orally (PO) once daily (QD) on days 2, 9, and 16. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 3 weeks.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- M D Anderson Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors who have received at least two lines of therapy; for the expansion phase: female patients with metastatic breast cancer who have received a maximum of three lines of therapy
- Absolute neutrophil count (ANC) >= 1,000/uL
- Platelets >= 100,000/uL
- Hemoglobin (Hgb) >= 9 g/dL
- Creatinine =< 1.5 x upper limit of normal (ULN)
- Prothrombin time (PT) within institutional guideline for biopsy procedure
- Total bilirubin =< 1.5 x ULN
- Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 3 x ULN for subjects with liver involvement with cancer)
- A known diabetic patient who is taking insulin or oral anti-diabetic therapy must have a hemoglobin A1C (HBA1C) =< 8% or a fasting serum glucose =< 110% ULN
- Patient will have a tumor suitable for fine-needle aspirates (FNA) and core biopsy for research purposes (determined by the treating physician)
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) or evaluable disease (e.g., bone metastasis or lesions which do not fulfill RECIST criteria for metastatic disease)
Patients with central nervous system (CNS) metastasis who have completed a course of therapy (for treatment of CNS metastasis) would be eligible for the study provided they are clinically stable for 1 month prior to entry as defined as:
- No evidence of new or enlarging CNS metastasis
- Off steroids and anticonvulsants
- Corrected QT (QTc) interval =< 450 msec (Bazett's formula)
- Negative serum pregnancy test beta-human chorionic gonadotropin (hCG) for patients of childbearing age
- For the dose escalation cohorts, patients must have received front-line, cytotoxic, systemic therapy (combination or single agent, with or without the addition of targeted agents) for advanced cancer
- For the expansion cohort, patients must have received no more than three lines of cytotoxic systemic therapy (combination or single agent, with or without the addition of targeted agents) for metastatic breast cancer; patients could have received paclitaxel in the adjuvant setting, but not in the metastatic setting
- The last line of therapy must have been administered > 21 days prior to initiation of treatment on this study
- Women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
- Both men and women and members of all races and ethnic groups are eligible for this trial
Exclusion Criteria:
- Patients may not be receiving any other investigational agents
- Patients taking a potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitor or inducer will be excluded; patients who have discontinued any of these medications must have a wash-out period of at least 5 days or at least 5 half-lives of the drug (whichever is longer) prior to the first dose MK-2206
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 or other agents used in the study
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, bradycardia, related to cardiac disease, bundle branch block, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment (Akt inhibitor MK2206 and paclitaxel)
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and Akt inhibitor MK2206 PO QD on days 2, 9, and 16.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Korrelative Studien
Korrelative Studien
Gegeben IV
PO gegeben
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Antitumor activity of the combination in metastatic breast cancer (Expansion phase)
Zeitfenster: Up to 3 weeks after completion of study treatment
|
Up to 3 weeks after completion of study treatment
|
MTD of the combination of MK-2206 and paclitaxel defined as the dose level in which less than or equal to 1 out of 6 patients develop dose limiting toxicity assessed using Common Terminology Criteria for Adverse Events version 4 (Phase I)
Zeitfenster: 21 days
|
21 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in average number of circulating tumor cells (CTCs)
Zeitfenster: Baseline to up to 2 weeks
|
Will be determined by chi-square analysis or Fisher's Exact test and compared by Student t-test.
|
Baseline to up to 2 weeks
|
Change in multiplex proteomics
Zeitfenster: Baseline to up to day 17
|
Baseline to up to day 17
|
|
Change in percentage of biomarkers assessed using immunohistochemistry
Zeitfenster: Baseline to up to 2 weeks
|
Baseline to up to 2 weeks
|
|
Change in percentage of marker of proliferation Ki-67 (Ki-67) positive cells
Zeitfenster: Baseline to up to 2 weeks
|
Will be calculated using a two-sided one-sample t-test, at a significance level of 0.05.
|
Baseline to up to 2 weeks
|
Change in reverse phase proteomic arrays (RPPA)
Zeitfenster: Baseline to up to day 8
|
Will be analyzed using the Wilcoxon rank test.
|
Baseline to up to day 8
|
Pharmacokinetic parameters of Akt inhibitor MK2206
Zeitfenster: On days 1-3, 5, 8, 16, 17, and 19 of course 1 and then on day 1 of all subsequent courses
|
Standard analyses for the pharmacokinetic endpoints will be conducted, including summary of descriptive measures, e.g., tabulation of frequencies for categorical variables, numerical (mean, range, standard deviation, 95% confidence intervals) and graphical (box plots, histograms) summary of the distribution for continuous endpoints, correlation analyses (Pearson and Spearman), and linear and nonlinear regression analyses, etc.
|
On days 1-3, 5, 8, 16, 17, and 19 of course 1 and then on day 1 of all subsequent courses
|
Pharmacokinetic parameters of paclitaxel
Zeitfenster: On days 1, 2, 15, and 16 of course 1
|
Standard analyses for the pharmacokinetic endpoints will be conducted, including summary of descriptive measures, e.g., tabulation of frequencies for categorical variables, numerical (mean, range, standard deviation, 95% confidence intervals) and graphical (box plots, histograms) summary of the distribution for continuous endpoints, correlation analyses (Pearson and Spearman), and linear and nonlinear regression analyses, etc.
|
On days 1, 2, 15, and 16 of course 1
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in expression of plasma markers
Zeitfenster: Baseline to up to day 17
|
The marker expression will be compared by Student t-test.
|
Baseline to up to day 17
|
PIK3CA mutation status
Zeitfenster: Up to day 17
|
Chi-square or Fisher's exact status will be used to calculate associations between PIK3CA status and clinical parameters.
|
Up to day 17
|
Prevalence of single nucleotide polymorphisms (SNPs) in PI3K pathway genes
Zeitfenster: Up to day 17
|
Descriptive analysis will be performed.
|
Up to day 17
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- NCI-2011-02562 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- P30CA016672 (US NIH Stipendium/Vertrag)
- U01CA062490 (US NIH Stipendium/Vertrag)
- U01CA062461 (US NIH Stipendium/Vertrag)
- 8739 (Andere Kennung: CTEP)
- 2010-0245 (Andere Kennung: M D Anderson Cancer Center)
- CDR0000690723
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Labor-Biomarker-Analyse
-
Vanderbilt University Medical Center4DMedicalAbgeschlossen
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Noch keine RekrutierungHIV-Infektionen | Hepatitis B
-
Duke UniversityZurückgezogenAntikoagulations- und Thrombose-Point-of-Care-Test (AT-POCT)Vereinigte Staaten
-
Columbia UniversityAbgeschlossen
-
McGill University Health Centre/Research Institute...Northwestern UniversityRekrutierungApnoe der FrühgeburtlichkeitKanada
-
Emory UniversityDermatology FoundationBeendetKutaner Lupus erythematodesVereinigte Staaten